Awakn Life Sciences Corp. announced it has signed a global licensing agreement with LTS Lohmann Therapie-Systeme AG. The agreement is for a proprietary S-ketamine formulation, administered sublingually via an oral thin film (OTF).

Awakn will have global exclusivity of its use in the treatment of Addiction, Anxiety Disorders, and Eating Disorders. LTS has successfully completed a Phase 1 clinical trial and filed patents in the US and key international markets of China, Canada, Europe, and Japan for this novel formulation of S-ketamine. Under the terms of the Agreement Awakn has secured access to this Phase 1 data and exclusive global rights to the proprietary formulation for use in the above indications.

Thereby ensuring strong intellectual property protection and potential to rapidly progress to late clinical stage trials. The sublingual S-ketamine formulation signifies a remarkable potential advancement in addiction treatment. Its sublingual administration offers potentially a faster onset of action, more precise dosing, and reduced potential for adverse effects compared to conventional delivery methods.

Safety, efficacy, and patient well-being are paramount in Awakn and LTS's commitment to transforming the treatment of addiction. The licensing agreement includes terms related to milestone payments, royalties, and commercial manufacturing of the drug product by LTS.